Long-term Outcomes of Pregnant Women With PAH

Status Recruiting

Clinical Trial Summary

The investigators intend to explore the characteristics and outcomes of pregnant women with PAH during different pregnancies and to provide applicable evidence for clinical practice.

Clinical Trial Description

Pulmonary arterial hypertension (PAH) is a fatal disease with progressive vascular resistance that leads to the loss of right heart function. Avoiding pregnancy is essential for PAH women. In recent years, maternal mortality in pregnant women with PAH has decreased mostly due to emerging advanced therapies for PAH and the progress in high-risk pregnancy management. Nevertheless, the maternal death rate in parturients with PAH remains high; therefore, contraception is still recommended for women diagnosed with PAH. However, some women develop this condition during pregnancy. With the two-child policy, families in China are allowed to have a second child. As a result, the number of PAH diagnoses during pregnancy may increase with the general increase in the number of pregnant women. Additionally, some patients develop PAH only during their second pregnancy. In order to investigate the incidence and clinical characteristics of pregnant women diagnosed with PAH during different pregnancies, this observational study aimed to analyze perinatal and pregnancy clinical data, to compare the perinatal status and maternal and infant outcomes of the first and second pregnancies complicated with PAH, establishing a clinical basis for the prenatal consultation, diagnosis, and treatment of pregnant women with PAH. ;

Study Design

Related Conditions & MeSH terms

Familial Primary Pulmonary Hypertension
Hypertension
Pulmonary Arterial Hypertension

Clinical Trial Details

NCT number	NCT04053296
Study type	Observational
Source	RenJi Hospital
Contact	Jieyan Shen, PhD
Phone	+8613701864819
Email	dr_jyshen@sina.com
Status	Recruiting
Phase
Start date	November 1, 2017
Completion date	December 31, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04076241` - Effects of Adding Yoga Respiratory Training to Osteopathic Manipulative Treatment in Pulmonary Arterial Hypertension	N/A
Completed	`NCT05521113` - Home-based Pulmonary Rehabilitation With Remote Monitoring in Pulmonary Arterial Hypertension
Recruiting	`NCT04972656` - Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial Hypertension	N/A
Completed	`NCT04908397` - Carnitine Consumption and Augmentation in Pulmonary Arterial Hypertension	Phase 1
Active, not recruiting	`NCT03288025` - Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE)	N/A
Completed	`NCT01959815` - Novel Screening Strategies for Scleroderma PAH
Recruiting	`NCT04266197` - Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study	Phase 2
Active, not recruiting	`NCT06092424` - High Altitude (HA) Residents With Pulmonary Vascular Diseseases (PVD), Pulmonary Artery Pressure (PAP) Assessed at HA (2840m) vs Sea Level (LA)	N/A
Enrolling by invitation	`NCT03683186` - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension	Phase 3
Terminated	`NCT02060487` - Effects of Oral Sildenafil on Mortality in Adults With PAH	Phase 4
Terminated	`NCT02253394` - The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study	Phase 4
Withdrawn	`NCT02958358` - FDG Uptake and Lung Blood Flow in PAH Before and After Treatment With Ambrisentan	N/A
Terminated	`NCT01953965` - Look at Way the Heart Functions in People With Pulmonary Hypertension (PH) Who Have Near Normal Right Ventricle (RV) Function and People With Pulmonary Hypertension Who Have Impaired RV Function. Using Imaging Studies PET Scan and Cardiac MRI.	Phase 2
Unknown status	`NCT01712997` - Study of the Initial Combination of Bosentan With Iloprost in the Treatment of Pulmonary Hypertension Patients	Phase 3
Not yet recruiting	`NCT01649739` - Vardenafil as add-on Therapy for Patients With Pulmonary Hypertension Treated With Inhaled Iloprost	Phase 4
Withdrawn	`NCT01723371` - Beta Blockers for Treatment of Pulmonary Arterial Hypertension in Children	Phase 1/Phase 2
Completed	`NCT01548950` - Drug Therapy and Surgery in Congenital Heart Disease With Pulmonary Hypertension	N/A
Completed	`NCT01165047` - Nitric Oxide, GeNO Nitrosyl Delivery System	Phase 2
Completed	`NCT00963027` - Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil	Phase 1
Completed	`NCT00902174` - Imatinib (QTI571) in Pulmonary Arterial Hypertension	Phase 3